Table 4.
Summary of variation in approach to implementing anaemia screening and MSSA decolonisation pathways, rates of implementation and primary outcome reporting
| Trial arm | Approach to diagnosing anaemia or MSSA decolonisation | Total number of procedures performed during trial 12-month measurement period (n range) | Procedures where records were provided (included in QIST analysis) (% range of total procedures performed) | Procedures for which pre-op pathway was implemented as part of QISTa (% range of total procedures performed) | Reported potential SSIs, n | All SSIs confirmed by IOCb (% range of reported potential SSIs) | IOC confirmed deep SSIs by causative organism (% range of procedures included in QIST) | Procedures requiring blood transfusion (% range) |
|---|---|---|---|---|---|---|---|---|
| Anaemia |
Variation in Hb thresholds for diagnosing anaemia was observed. Lower limits ranged from 105 to 115g/L and upper limits ranged from 115 to 129g/L. Not all Trusts used sex-dependant thresholds |
397–2805 | 20.4–100% | 16.4–98.1 | 0–25 | 11–100% |
MSSA: 0–0.7% Anyc: 0–1.1% |
0–11.6% |
| Infection |
6 Trusts screened and only decolonised MSSA-positive patients. MSSA-positive rate ranged from 21.9 to 31.2% 10 Trusts decolonised all patients without screening |
457–2786 | 22.6–100% | 0–94.1% | 0–75 | 9–100% |
MSSA: 0–0.7% Anyc: 0–2.1% |
0–7.7% |